These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31344163)

  • 1. [Waldenström macroglobulinemia. Experience in 31 patients].
    Cardemil D; León P; Peña C; Valladares X; Cabrera ME
    Rev Med Chil; 2019 Mar; 147(3):275-280. PubMed ID: 31344163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
    Durot E; Tomowiak C; Michallet AS; Dupuis J; Hivert B; Leprêtre S; Toussaint E; Godet S; Merabet F; Van Den Neste E; Ivanoff S; Roussel X; Zini JM; Regny C; Lemal R; Sutton L; Perrot A; Le Dû K; Kanagaratnam L; Morel P; Leblond V; Delmer A
    Br J Haematol; 2017 Nov; 179(3):439-448. PubMed ID: 28770576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Osteonecrosis developing after rituximab-containing chemotherapy for Waldenström macroglobulinemia].
    Nakamura F; Hirai R; Higo T; Togano T; Sekine R
    Rinsho Ketsueki; 2018; 59(3):305-309. PubMed ID: 29618689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).
    Buske C; Hoster E; Dreyling M; Eimermacher H; Wandt H; Metzner B; Fuchs R; Bittenbring J; Woermann B; Hohloch K; Hess G; Ludwig WD; Schimke J; Schmitz S; Kneba M; Reiser M; Graeven U; Klapper W; Unterhalt M; Hiddemann W;
    Leukemia; 2009 Jan; 23(1):153-61. PubMed ID: 18818699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia.
    Dimopoulos MA; Hamilos G; Zervas K; Symeonidis A; Kouvatseas G; Roussou P; Gika D; Karmiris T; Bourantas K; Zomas A; Mitsouli C; Xilouri I; Vervessou E; Matsis K; Anagnostopoulos N; Economopoulos T;
    Ann Oncol; 2003 Aug; 14(8):1299-305. PubMed ID: 12881396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
    Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
    Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 44-Year-Old Man with Waldenstrom Macroglobulinemia and Bilateral Maxillary Sinusitis.
    Trianto HB; Wardhani SO
    Acta Med Indones; 2016 Jul; 48(3):221-227. PubMed ID: 27840358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinicopathologic features of lymphoplasmacytic lymphoma].
    Liu EB; Zhang PH; Li ZQ; Sun Q; Yang QY; Fang LH; Sun FJ; Qiu LG
    Zhonghua Bing Li Xue Za Zhi; 2010 May; 39(5):308-12. PubMed ID: 20654153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemia.
    Herth I; Hensel M; Rieger M; Horstmann K; Hiddemann W; Dreyling M; Koniczek S; Witzens-Harig M; Ho AD
    Leuk Lymphoma; 2015 Jan; 56(1):97-102. PubMed ID: 24724778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating low CD4
    Cao X; Kong YL; Wang L; Liang JH; Xia Y; Zhu HY; Fan L; Jiang SH; Liu H; Li JY; Xu W
    Ann Hematol; 2021 Apr; 100(4):995-1002. PubMed ID: 33651193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib-based chemotherapy for patients with Waldenström macroglobulinemia: a single-center experience.
    Liu Z; Jiang S; Gu J; Liu H; Song G; Cao X
    Ann Hematol; 2023 Jan; 102(1):167-174. PubMed ID: 36374339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Waldenstrom macroglobulinemia with CD5+ expression presented as cryoglobulinemic glomerulonephropathy: a case report.
    Kim YL; Gong SJ; Hwang YH; Joo JE; Cho YU; Lee JA; Sung SA; Lee SY; Kim NY
    J Korean Med Sci; 2011 Jun; 26(6):824-8. PubMed ID: 21655071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia.
    Olszewski AJ; Chen C; Gutman R; Treon SP; Castillo JJ
    Br J Haematol; 2017 Oct; 179(1):106-115. PubMed ID: 28677830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019.
    Chien HC; Morreall D; Patil V; Rasmussen KM; Yong CM; Li CY; Passey DG; Burningham Z; Sauer BC; Halwani AS
    Am J Hematol; 2021 Jun; 96(6):E184-E187. PubMed ID: 33606890
    [No Abstract]   [Full Text] [Related]  

  • 15. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
    Paludo J; Abeykoon JP; Shreders A; Ansell SM; Kumar S; Ailawadhi S; King RL; Koehler AB; Reeder CB; Buadi FK; Dispenzieri A; Lacy MQ; Dingli D; Witzig TE; Go RS; Gonsalves WI; Kourelis T; Warsame R; Leung N; Habermann TM; Hayman S; Lin Y; Kyle RA; Rajkumar SV; Gertz MA; Kapoor P
    Ann Hematol; 2018 Aug; 97(8):1417-1425. PubMed ID: 29610969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
    J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical features of 16 cases of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia].
    Wang JJ; Jing HM; Shen HW; Xu JS; Li M; Gao ZF; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1494-8. PubMed ID: 21176358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis.
    Annibali O; Petrucci MT; Martini V; Tirindelli MC; Levi A; Fossati C; Del Bianco P; Mandelli F; Foa R; Avvisati G
    Cancer; 2005 Feb; 103(3):582-7. PubMed ID: 15611977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2017 Feb; 92(2):209-217. PubMed ID: 28094456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of diffuse large B-cell lymphoma following Waldenström's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab.
    Uchino K; Sameshima H; Miyamoto T; Iino T; Kato K; Henzan H; Aoki K; Nagafuji K; Gondo H; Harada M
    Intern Med; 2004 Feb; 43(2):131-4. PubMed ID: 15005256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.